CAMBRIDGE COMBINATORIAL™ ANNOUNCES NAME CHANGE
‘Cambridge Discovery Chemistry™’ chosen to reflect medicinal chemistry component of Company’s approach
Cambridge, UK …
Cambridge Combinatorial Ltd, a wholly owned subsidiary of Oxford Molecular Group plc (London Stock Exchange: OMG), today announced that in future it will trade under the name of Cambridge Discovery Chemistry, which more accurately reflects the breadth of the Company’s business and scientific expertise. The name change will be effective from October 1999.Dr Allan Marchington, Chief Executive, said "We have always seen our strength to be in medicinal chemistry in combination with parallel synthesis expertise and commitment to innovation. The range of collaborations established illustrates this and our new name has been chosen to better express the full range of services we offer."
The Company’s collaborations support this belief: Cambridge Combinatorial has reached agreements with partners in the pharmaceutical, agrochemical and biotechnology industries. Within the pharmaceutical industry, the Company’s collaborations have covered library synthesis, lead optimisation, and process research and development.
"As the chemistry outsourcing market matures, we feel that the term ‘combinatorial chemistry’ will increasingly be linked to a commodity market based simply on compound numbers," Dr Marchington added. "We believe Cambridge Discovery Chemistry better describes our own approach of bringing genuine benefits to our partners through novel chemistries, molecular design, targeted libraries, integrated informatics, and proven industry experience."
For further information, please contact:
Cambridge Discovery Chemistry
(Formerly known as Cambridge Combinatorial)
David T Phillips, Vice-President, Business Development
Tel: +44 1223 722400
HCC·De Facto Group plc
Chris Gardner, HCC·De Facto Group plc
TEL: +44 171 496 3300
Notes to editors
Cambridge Combinatorial Limited
Cambridge Combinatorial Limited provides world-class,
innovative chemistry services to accelerate discovery and process research, servicing the
pharmaceutical, agrochemical and biotechnology industries. The Company is a wholly owned
subsidiary of Oxford Molecular Group Plc. Cambridge Combinatorial has developed leading
technologies for discovery research including innovative molecular design, novel
chemistries, new synthetic chemistry platforms and a comprehensive integrated informatics
system. The company acts as an extension to the resources of its collaborators with
solutions for discovery research including medicinal and combinatorial chemistry for lead
generation, validation, optimisation and technology transfer as required.
Cambridge Combinatorial supplies the molecular design and synthesis arm of Oxford Molecular’s Collaborative Discovery. Collaborative Discovery acts as a central point for multi-disciplinary research projects involving both chemistry and biology research. Cambridge Combinatorial has secured many discovery collaborations with a range of pharmaceutical, agrochemical and biotechnology companies spanning the US, Japan and Europe these include: Merck & Co. Inc., Pfizer, Procter & Gamble Pharmaceuticals Inc., Rohm & Haas, Alizyme, Solvay Pharmaceuticals, Mitsubishi Chemical Corporation, Yamanouchi and Fujisawa.
Oxford Molecular Group plc
Oxford Molecular is a leading provider of discovery and software solutions to the life
sciences market. The Company seeks to deliver excellence in all its products and services
and to help its customers benefit from the synergy that is created from the integration of
state-of-the-art chemistry, biology and information technology infrastructure.
The Discovery Solutions Division offers discovery research through collaboration, by providing world-class innovative technologies in chemistry and biology which intimately match customer needs and add value to their research programmes. The Software Solutions Division supplies enterprise-wide software and information technology solutions for research across the entire drug discovery process. Innovative and superior products target customer needs for excellence in each area of discovery research; and together they form integrated solutions that add value to the flow of information through the customer’s research process.
The Company has its headquarters in Oxford, England and has operations throughout the USA as well as sales offices and agents around the world